Biopharmaceuticals Market by Product Type (Monoclonal Antibodies, Purified Proteins, Recombinant Growth Factors), Services (Compendial & Multi Compendial Laboratory Testing, Custom Testing or Customer Proprietary Testing, Laboratory Testing), Raw Material Type, Application - Global Forecast 2024-2030

360iResearch Analyst
Want to know more about the biopharmaceuticals market or any specific requirement? Ketan helps you find what you're looking for.
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[182 Pages Report] The Biopharmaceuticals Market size was estimated at USD 574.04 billion in 2023 and expected to reach USD 627.19 billion in 2024, at a CAGR 9.74% to reach USD 1,100.51 billion by 2030.

Biopharmaceuticals Market
To learn more about this report, request a free PDF copy

Biopharmaceuticals, also known as biologics, refer to medical drugs produced using biotechnology. They are comprised of proteins and nucleic acids and are used for therapeutic or diagnostic purposes. Unlike traditional pharmaceuticals, which are chemically synthesized and have well-defined molecular structures, biopharmaceuticals are derived from living organisms. These organisms can include bacteria, yeast, or mammalian cells that are genetically engineered to produce the desired therapeutic substances, such as hormones, antibodies, or vaccines. The rising incidences of chronic and infectious diseases such as cancer, cardiovascular disorders, tuberculosis, Crohn's disease, and arthritis have created a need for novel biopharmaceuticals. Additionally, the expansion of healthcare infrastructure, growing access to healthcare services, and supportive government initiatives that promote the discovery and development of new pharmaceuticals have further generated growth for the industry. However, maintaining cold chain logistics for temperature-sensitive products can prove to be a hurdle for biopharmaceuticals. Furthermore, complexities in manufacturing processes can also significantly impede the widespread growth of the industry. However, key players are investing in new technologies such as AI/ML and data analytics to streamline and accelerate the production of biopharmaceuticals. Moreover, the adoption of personalized medicine and advancement in genomic research can create new opportunities for the growth of the industry.

Regional Insights

The Americas region, particularly the U.S. and Canada, remains a highly advanced region in biopharmaceutical research and development, spurred by a combination of robust intellectual property rights, a science-driven regulatory framework, and a competitive market landscape. The U.S. Food and Drug Administration (FDA) continuously adapts to the rapid pace of innovation, ensuring safe and effective treatments reach patients. The presence of several key players in the biotechnological sector and a robust healthcare infrastructure that provides reimbursements and health insurance have led to the growth of the biopharmaceutical industry. The EU region boasts a robust ground for research and development in the sphere of life sciences and biotechnology. Stringent regulations and standards pertaining to the development of biopharmaceuticals have created a standardized, systematic, and safe environment for innovations in biopharmaceuticals. The European Medicines Agency (EMA) in the EU plays a central role in facilitating the development and accessibility of new therapies. Strong public-private partnerships and a commitment to healthcare innovation define the EU's consumer needs and behavior, which lean towards high-quality, sustainable healthcare solutions. In the APAC region, a growing aging population and government incentives and initiatives for promoting access to affordable healthcare services have led to a need for biopharmaceuticals. Japan, with its established pharmaceutical sector, is characterized by significant spending on healthcare solutions. Countries in the APAC region, such as India and China, have focused on the cost-effective manufacturing of biopharmaceuticals and often invest in biosimilar production.

Market Dynamics

The market dynamics represent an ever-changing landscape of the Biopharmaceuticals Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Prevalence of Chronic Diseases and Need for Targeted Biopharmaceuticals
    • Rising Investments in Vaccine and Drugs Development
    • Attractive Reimbursement Policies for Biopharmaceuticals
  • Market Restraints
    • Raw Material Supply Chain Disruptions and High Cost of Drug Development
  • Market Opportunities
    • Advancements in Biopharmaceutical Manufacturing and Testing Technologies
    • Emerging Trends of Outsourcing Biologics and Vaccine Manufacturing
  • Market Challenges
    • Stringent Regulatory Framework for Drug Manufacturing and Time-Consuming Clinical Trials
Market Segmentation Analysis
  • Product Type: Ongoing R&D initiatives to promote innovations in the field of monoclonal antibodies

    Monoclonal antibodies (mAbs) are proteins that mimic the immune system's capacity to fight off harmful pathogens. They are custom-designed to target specific antigens, such as those found on the surface of cancer cells. Purified proteins include enzymes, hormones, and other proteins that have therapeutic action. These proteins are employed in the treatment of enzymatic disorders, hormonal deficiencies, and other conditions where supplementation of natural proteins is needed. Recombinant growth factors are proteins that stimulate cellular growth, proliferation, healing, and cellular differentiation. They are widely used in various medical treatments, including neutropenia and wound healing. Recombinant hormones are genetically engineered hormones identical to those produced naturally in the human body, most commonly insulin, human growth hormone, and erythropoietin. Recombinant proteins cover a broad range of biologically active proteins, including enzymes, cytokines, and blood factors, manufactured using recombinant DNA technology. Synthetic Immunomodulators are agents that can modify the immune response by enhancing or suppressing it. They're used in treating autoimmune diseases and cancers and in organ transplantation. They are preferred when modulation of the immune system is necessary to treat disease or prevent rejection in organ transplant scenarios. Vaccines are biological preparations that aim to provide active acquired immunity to particular infectious diseases. They can contain live attenuated or killed forms of the pathogenic microorganism, its toxins, or one of its surface proteins.

  • Services: Need for compendial & multi compendial laboratory testing to ensure compliance with regulations

    In the biopharmaceutical industry, compendial & multicompendial laboratory testing services are essential for ensuring that products meet the strict standards and regulations of various pharmacopeias, such as the United States Pharmacopeia (USP), European Pharmacopeia (EP), or Japanese Pharmacopeia (JP). These tests are required for quality control and to ensure the safety, hygiene, efficacy, and quality of biopharmaceuticals before they reach the market. Custom testing or customer proprietary testing is tailored to meet the unique needs of a biopharmaceutical company. Unlike compendial testing, which follows established guidelines, custom testing is developed specifically for a company's proprietary products or processes. This can include stability testing, method development, validation, or testing for impurities that are not covered by standard compendial methods. Laboratory testing, in a broader sense, encompasses various types of analyses performed to ensure that biopharmaceutical products adhere to all necessary quality standards and regulations. This can extend from raw material testing to final product release testing, including but not limited to bioanalytical services, microbiological evaluation, and environmental monitoring.

  • Raw Material Type: Efforts to develop potent APIs to diagnose, cure, or mitigate disease conditions

    The active pharmaceutical ingredient (API) is the primary component of any drug product that produces the intended effects. APIs are crucial for the development of new drug formulations and play a significant role in the creation of biopharmaceutical products. They are highly regulated to ensure efficacy and safety. Highly potent APIs are often preferred in treatments requiring lower dosage, while for chronic conditions, consistent and cost-effective supply is key. Formulation excipients are inactive substances used for the purpose of bulking up formulations that contain potent active ingredients in small amounts or to confer a therapeutic enhancement, such as facilitating drug absorption or stability. The choice of excipients is dependent on the drug's delivery method, the required dosage form, and stability requirements. Excipients must be compatible with the API and should not affect the drug's efficacy or safety profile.

  • Application: Changes in lifestyles leading to the need for treatment strategies for cardiovascular diseases

    The biopharmaceuticals used for autoimmune disorders often focus on the modulation of the immune system to prevent it from attacking the patient's own cells. These medications are crucial for conditions such as rheumatoid arthritis, lupus, and type 1 diabetes. Biopharmaceuticals address cardiovascular diseases by offering treatments that can help manage conditions such as heart failure, hypercholesterolemia, and hypertension. Hormonal disorders such as diabetes and thyroid dysfunctions are managed through biopharmaceuticals that aim to replace or regulate hormone levels. Biopharmaceuticals in immunology are typically designed to treat immune-mediated diseases by targeting specific immune cells or pathways. Targeted therapies that reduce systemic immunosuppression are preferred to decrease the risk of infections. Biopharmaceuticals for inflammatory and infectious diseases include antibiotics and anti-inflammatory drugs that seek to improve upon the efficacy of traditional small-molecule treatments. The focus is on treatments that can overcome drug resistance while minimizing potential side effects and toxicity. Biopharmaceuticals tailored for metabolic disorders offer treatments for diseases such as obesity, osteoporosis, and dyslipidemia. Biopharmaceuticals that can reduce the risk of cardiovascular events alongside managing metabolic disorders are highly valued. Biopharmaceuticals in the form of enzyme replacement therapies and monoclonal antibodies target neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease. Therapeutics that are able to cross the blood-brain barrier (BBB) and offer modulatory effects on neuroinflammation are in need. The use of biopharmaceuticals in oncology has driven several improvements in cancer treatment, with drugs that can specifically target cancer cells and modulate the immune system to combat the disease.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Biopharmaceuticals Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Biopharmaceuticals Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Biopharmaceuticals Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Biopharmaceuticals Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Biopharmaceuticals Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Biopharmaceuticals Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Biopharmaceuticals Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Biopharmaceuticals Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Biopharmaceuticals Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Biopharmaceuticals Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biopharmaceuticals Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biopharmaceuticals Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion

    AstraZeneca entered into a definitive agreement to purchase Icosavax, a vaccine company specializing in the development of candidates designed to combat diseases caused by respiratory viruses, in a deal valued at USD 1.1 billion. This strategic move reflects AstraZeneca's commitment to expanding its vaccine portfolio and also positions the company to enhance its infectious disease capabilities by leveraging Icosavax's vaccine technology. [Published On: 2023-12-12]

  • LEQEMBI Intravenous Infusion (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20

    Eisai Co., Ltd. announced the impending release of their therapy LEQEMBI Intravenous Infusion (lecanemab) in Japan. Formulated as a humanized monoclonal antibody targeting soluble aggregated amyloid-beta (Aβ), this innovative treatment for Alzheimer’s disease has also been included in the Japan National Health Insurance (NHI) Drug Price List. This target-specific, anti-amyloid therapeutic option would be available in two dosage strengths, 200 mg, and 500mg, signifying a major advancement in the management of Alzheimer's disease. [Published On: 2023-12-12]

  • HHS Announces Details of Partnership with Regeneron to Develop Life-Saving Monoclonal Antibodies

    The U.S. Department of Health and Human Services (HHS) has officially announced refinements to its partnership with biotechnology firm Regeneron Pharmaceuticals in a concerted effort to advance the development of monoclonal antibodies critical for combating COVID-19. This collaboration, fostered under Project NextGen, signifies a strategic move to advance the nation's preparedness against emerging strains and variants of the virus. [Published On: 2023-09-08]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biopharmaceuticals Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Abgenex, Amgen Inc., AstraZeneca PLC, Avidea Technologies, Bayer AG, Bio-Techne Corporation, Biogen Inc., bioMérieux SA, Bristol-Myers Squibb Company, BTL Biotechno Labs Pvt. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals, GlaxoSmithKline PLC, Ipsen Pharma, Johnson & Johnson Services, Inc., LG Chem Life Sciences Innovation Center, Inc., Merck & Co., Inc., Nordic BioSite, Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Biopharmaceuticals Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the Biopharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product Type
    • Monoclonal Antibodies
    • Purified Proteins
    • Recombinant Growth Factors
    • Recombinant Hormone
    • Recombinant Proteins
    • Synthetic Immunomodulators
    • Vaccines
  • Services
    • Compendial & Multi Compendial Laboratory Testing
    • Custom Testing or Customer Proprietary Testing
    • Laboratory Testing
  • Raw Material Type
    • Active Pharmaceutical Ingredient
    • Formulation Excipients
  • Application
    • Autoimmune Disorders
    • Cardiovascular Diseases
    • Hormonal Disorders
    • Immunology
    • Inflammatory & Infectious Diseases
    • Metabolic Disorders
    • Neurological Diseases
    • Oncology

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Biopharmaceuticals Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Biopharmaceuticals Market, by Product Type
  7. Biopharmaceuticals Market, by Services
  8. Biopharmaceuticals Market, by Raw Material Type
  9. Biopharmaceuticals Market, by Application
  10. Americas Biopharmaceuticals Market
  11. Asia-Pacific Biopharmaceuticals Market
  12. Europe, Middle East & Africa Biopharmaceuticals Market
  13. Competitive Landscape
  14. Competitive Portfolio
  15. List of Figures [Total: 24]
  16. List of Tables [Total: 392]
  17. List of Companies Mentioned [Total: 27]
The Advancements in Biopharmaceutical Manufacturing and Testing Technologies
October 18, 2023
The Advancements in Biopharmaceutical Manufacturing and Testing Technologies
The world is progressing at an incredible pace, and the healthcare industry is not far behind. In the past few decades, the ever-evolving biopharmaceutical manufacturing and testing technologies have provided countless benefits to patients across the globe. Today, scientists continue to push the boundaries of science to provide superior-quality medications and treatments that are based on the latest discoveries in the field of biopharmaceuticals.

The Importance of Biopharmaceuticals:

Biopharmaceuticals are medications and treatments produced from living organisms that are used to treat several medical conditions, including cancer, autoimmune diseases, diabetes, and rare genetic disorders. They are responsible for revolutionizing the healthcare industry by providing a more individualized approach to medication administration.

Advancements in Biopharmaceutical Manufacturing:

Biopharmaceutical manufacturing plays a significant role in the production of high-quality drugs. The use of advanced technologies, such as single-use systems, cell-culture systems, and automation, has resulted in minimizing contamination and reducing the need for expensive equipment and infrastructure. The use of novel biomanufacturing technologies is contributing to more efficient, cost-effective, and reliable production of biopharmaceuticals.

Testing Technologies:

Biopharmaceutical testing is a critical aspect of the drug development process, ensuring that the medication administered is safe, effective, and free from contaminants. The introduction of new testing technologies has enabled the tackling of several challenges associated with traditional testing methods. Current techniques include the use of mass spectrometry, flow cytometry, and immunoassays. The use of these cutting-edge technologies has resulted in faster drug release and brought down the overall cost of the drugs.

Robotics and Artificial Intelligence:

The biopharmaceutical manufacturing industry has been profoundly impacted by continuous robotics and artificial intelligence (AI) advancements. Robotic technologies allow for precise and automated testing procedures, minimizing the usage of time and resources. Artificial intelligence tools help analyze and interpret the vast amount of data generated during the drug development, testing, and manufacturing process, resulting in better targeting of drug development activities.

The Future of Biopharmaceutical Manufacturing and Testing Technologies:

The biopharmaceutical industry is already reaping the countless benefits of modernizing its processes and integrating advanced technologies. The future of biopharmaceutical manufacturing and testing looks incredibly promising, with further innovation and evolution expected. Up-and-coming technological trends such as virtual reality, big data, and gene editing can help accelerate the discovery of new drugs, promote patient-centric treatment paradigms, and pivot the industry towards more personalized drug development.

The life sciences industry is unceasingly evolving. The advancements in biopharmaceutical manufacturing and testing technologies have been the driving force behind it. New innovations and evolutionary shifts have enabled the production of drugs much faster, more cost-effective, and more precise than in the past. They helped in the improvement of drug quality, faster release of drugs, and making new, innovative drugs available to the patients. Thanks to these advancements, the future of the biopharmaceutical industry looks brighter than ever.

Frequently Asked Questions
  1. How big is the Biopharmaceuticals Market?
    Ans. The Global Biopharmaceuticals Market size was estimated at USD 574.04 billion in 2023 and expected to reach USD 627.19 billion in 2024.
  2. What is the Biopharmaceuticals Market growth?
    Ans. The Global Biopharmaceuticals Market to grow USD 1,100.51 billion by 2030, at a CAGR of 9.74%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.